Interpretation on the Clinical Application Guidelines on Chinese Patent Medicine in the Treatment for Ulcerative Colitis
-
摘要: 《中成药治疗溃疡性结肠炎临床应用指南》由北京中医药大学东方医院、北京大学第一医院牵头，联合全国29家三级甲等医院及高校、科研院所共同制定，2022年12月发表于《中华消化杂志》。该指南针对不同严重程度、治疗目标定位下的中成药口服和(或)灌肠治疗溃疡性结肠炎提出了12条推荐意见，推荐口服及灌肠中成药6种。本文将从该指南的制定背景、方法以及相关内容进行解读。Abstract: The Clinical Application Guidelines on Chinese Patent Medicine in the Treatment for Ulcerative Colitis was led by Dongfang Hospital Beijing University of Traditional Chinese Medicine and Peking University First Hospital, and jointly formulated by 29 tertiary hospitals, universities and research institutes across the country. It was published in the Chinese Journal of Digestion in December 2022. The guidelines put forward 12 recommendations for the oral and enema of proprietary Chinese patent medicines for the treatment of ulcerative colitis with different severity and treatment goals, and a total of six oral and enema proprietary Chinese patent medicines were recommended. This article will Interpret the background, methodology and related content of the guidelines.
-
Key words:
- Chinese patent medicine /
- ulcerative colitis /
- guideline /
- interpretation
-
-
表 1 推荐意见摘要
用药方式 严重程度 治疗定位 适用条件 推荐方案 推荐级别 口服 轻中度UC活动期 改善临床症状 中医辨证为大肠湿热证，可见腹泻、黏液脓血便、腹痛、里急后重；也可伴有肛门灼热、发热、口干口苦、小便黄。 虎地肠溶胶囊单独口服 1B 五味苦参肠溶胶囊单独口服 1B 虎地肠溶胶囊联合美沙拉嗪口服 1B 诱导缓解 五味苦参肠溶胶囊单独口服 1B 虎地肠溶胶囊联合奥沙拉秦口服 1B UC缓解期 维持缓解 UC缓解期 口服五味苦参肠溶胶囊、虎地肠溶胶囊逐渐减量并联合参苓白术制剂 专家共识 灌肠 轻中度UC活动期 改善临床症状 轻中度UC活动期均可使用，无需辨证。 康复新液单独灌肠 2C 八味锡类散单独灌肠 2B 诱导缓解 八味锡类散单独灌肠 2B 康复新液灌肠联合美沙拉嗪口服 1B 复方黄柏液涂剂灌肠联合美沙拉嗪口服 2C 口服联合灌肠 轻中度UC活动期 诱导缓解 中医辨证为大肠湿热证，可见腹泻、黏液脓血便、腹痛、里急后重；也可伴有肛门灼热、发热、口干口苦、小便黄。 口服中成药：虎地肠溶胶囊、五味苦参肠溶胶囊；灌肠中成药：八味锡类散、康复新液 专家共识 注：1为强推荐，2为弱推荐，0为暂不明确，-1为反对，-2为不建议；A为高质量，B为中等质量，C为低质量，D为极低质量；针对重度UC活动期，暂无推荐意见，建议治疗参照现行西医指南。 
下载: 导出CSV
-
[1] 李军祥, 陈誩. 溃疡性结肠炎中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志, 2018, 26(2): 105-111, 120. https://zxyxh.whuhzzs.com/article/doi/10.3969/j.issn.1671-038X.2018.02.01
[2] Cui GL, Yuan AP. A systematic review of epidemiology and risk factors associated with Chinese inflammatory bowel disease[J]. Front Med(Lausanne), 2018, 5: 183.
[3] APDW 2004 Chinese IBD Working Group. Retrospective analysis of 515 cases of Crohn's disease hospitalization in China: nationwide study from 1990 to 2003[J]. J Gastroenterol Hepatol, 2006, 21(6): 1009-1015. doi: 10.1111/j.1440-1746.2006.04140.x
[4] Chow DKL, Leong RWL, Tsoi KKF, et al. Long-term follow-up of ulcerative colitis in the Chinese population[J]. Am J Gastroenterol, 2009, 104(3): 647-654.
[5] 吴开春, 梁洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中国实用内科杂志, 2018, 38(9): 796-813. doi: 10.19538/j.nk2018090106
[6] Chudy-Onwugaje KO, Christian KE, Farraye FA, et al. A state-of-the-art review of new and emerging therapies for the treatment of IBD[J]. Inflamm Bowel Dis, 2019, 25(5): 820-830. doi: 10.1093/ibd/izy327
[7] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7650): 924-926. doi: 10.1136/bmj.39489.470347.AD
[8] Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64(4): 401-406. doi: 10.1016/j.jclinepi.2010.07.015
[9] 秦书敏, 张海燕, 吴皓萌, 等. 基于现代文献的溃疡性结肠炎证候及证素分布特点研究[J]. 环球中医药, 2021, 14(3): 389-394. doi: 10.3969/j.issn.1674-1749.2021.03.005
[10] 岳宏, 王天芳, 陈剑明, 等. 溃疡性结肠炎常见中医证候及证候要素的现代文献研究[J]. 北京中医药大学学报, 2010, 33(5): 306-308. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYB201005005.htm
[11] 陈新林, 张长荣, 王丹丹, 等. 溃疡性结肠炎证候分布的文献研究[J]. 中华中医药学刊, 2017, 35(2): 378-381. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS201702034.htm
[12] 姜慧, 李军祥, 谭祥, 等. 李军祥教授治疗溃疡性结肠炎经验[J]. 中国中西医结合消化杂志, 2019, 27(3): 232-235. https://zxyxh.whuhzzs.com/article/doi/10.3969/j.issn.1671-038X.2019.03.16
[13] 沈洪, 朱磊, 胡乃中, 等. 虎地肠溶胶囊联合美沙拉秦肠溶片治疗活动期溃疡性结肠炎多中心、随机对照、双盲双模拟的临床研究[J]. 中国中西医结合杂志, 2019, 39(11): 1326-1331. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201911012.htm
[14] Tong ZQ, Yang B, Chen BY, et al. A multi-center, randomized, single-blind, controlled clinical study on the efficacy of composite Sophora colon-soluble capsules in treating ulcerative colitis[J]. Chin J Integr Med, 2010, 16(6): 486-492.
[15] 仝战旗, 杨波, 童新元, 等. 复方苦参结肠溶胶囊治疗湿热内蕴型溃疡性结肠炎多中心、随机、双盲、对照研究[J]. 中国中西医结合杂志, 2011, 31(2): 172-176. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201102009.htm
[16] Gong Y, Zha Q, Li L, et al. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study[J]. J Ethnopharmacol, 2012, 141(2): 592-598.
[17] 潘智, 邵赛丹, 黄登, 等. 虎地肠溶胶囊联合奥沙拉秦对慢性溃疡性结肠炎患者肠黏膜病变、血清炎性因子及NGAL和MMP-9表达影响[J]. 浙江医学, 2021, 43(21): 2337-2340. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJYE202121015.htm
[18] Gong W, Lv NH, Wang BM, et al. Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study[J]. Dig Dis Sci, 2012, 57(2): 503-507.
[19] 唐勤富, 曾伟. 康复新液联合美沙拉嗪对老年溃疡性结肠炎患者炎性因子、凝血功能的影响[J]. 现代中西医结合杂志, 2016, 25(26): 2911-2913. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH201626021.htm
[20] 刘剑, 刘洁, 任宏颖, 等. 康复新液灌肠治疗溃疡性结肠炎疗效观察[J]. 中国医院药学杂志, 2011, 31(22): 1888-1889, 1892. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ201122018.htm
[21] 潘燕, 欧阳钦. 八味锡类散灌肠对溃疡性结肠炎的治疗作用及其机制研究[J]. 中国中西医结合杂志, 2014, 34(1): 27-30. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201401008.htm
[22] 韩志宏, 托静美, 王燕平, 等. 康复新液联合美沙拉嗪治疗溃疡性结肠炎疗效观察[J]. 海南医学, 2016, 27(7): 1147-1149. https://www.cnki.com.cn/Article/CJFDTOTAL-HAIN201607040.htm
[23] 薛雾松, 刘仍海. 康复新液对老年UC患者的治疗效果及对血清MDA、SOD、hs-CRP水平的影响[J]. 解放军预防医学杂志, 2018, 36(10): 1248-1250. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYX201810006.htm
[24] 张烨, 李春涛, 鲁蕾, 等. 复方黄柏液灌肠联合美沙拉嗪对溃疡性结肠炎患者黏附因子的影响及疗效分析[J]. 临床消化病杂志, 2019, 31(5): 312-315. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXH201905015.htm
-